强生探讨竞购生物制药公司Intra-Cellular Therapies

界面
13 Jan

1月13日消息,知情人士称,强生公司正在探索收购一家生物制药公司Intra-Cellular Therapies。根据LSEG的数据,Intra-Cellular的市值约为100亿美元。知情人士称,谈判仍在进行中,交易还不确定,并补充说还可能出现其他潜在的收购者。(彭博)

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10